Proliferation kinetics and differentiation potential of ex vivo expanded human bone marrow stromal cells: Implications for their use in cell therapy

被引:578
作者
Banfi, A
Muraglia, A
Dozin, B
Mastrogiacomo, M
Cancedda, R
Quarto, R
机构
[1] Ist Nazl Ric Canc, Ctr Biotechnol Avanzate, Lab Differenziamento Cellulare, I-16132 Genoa, Italy
[2] Univ Genoa, Dipartimento Oncol Biol Genet, Genoa, Italy
关键词
chondrogenesis; osteogenesis; adipogenesis; bone marrow stromal cells; cell therapy;
D O I
10.1016/S0301-472X(00)00160-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Bone marrow stromal cells (BMSC) are an attractive target for novel strategies in the gene/cell therapy of hematologic and skeletal pathologies, involving BMSC in vitro expansion/transfection and reinfusion. We investigated the effects of in vitro expansion on BMSC pluripotentiality, proliferative ability, and bone-forming efficiency in vivo. Material and Methods. BMSC from three marrow donors were cultured to determine their growth kinetics. At each passage, their differentiation potential was verified by culture in inductive media and staining with alizarin red, alcian blue, or Sudan black, and by immunostaining for osteocalcin or collagen II. First passage cells were compared to fresh marrow for their bone-forming efficiency in vivo. Stromal cell clones were isolated from five donors and characterized for their multidifferentiation ability. The lifespan and differentiation kinetics of five of these clones were determined. Results. After the first passage, BMSC had a markedly diminish proliferation rate and gradually lost their multiple differentiation potential. Their bone-forming efficiency in vivo was reduced by about 36 times at first confluence as compared to fresh bone marrow. Experiments on the clones yielded comparable results. Conclusions. Culture expansion causes BMSC to gradually lose their early progenitor properties. Both the duration and the conditions of culture could be crucial to successful clinical use of these cells and must be considered when designing novel therapeutic strategies involving stromal mesenchymal progenitor manipulation and reinfusion. (C) 2000 International Society for Experimental Hematology. Published by Elsevier Science Inc.
引用
收藏
页码:707 / 715
页数:9
相关论文
共 33 条
[1]  
BARBOT C, 1994, NOUV REV FR HEMATOL, V36, P325
[2]   BONE-MARROW CONNECTIVE-TISSUE AND THE HEMATOPOIETIC MICRO-ENVIRONMENT [J].
BENTLEY, SA .
BRITISH JOURNAL OF HAEMATOLOGY, 1982, 50 (01) :1-6
[3]  
BERESFORD JN, 1989, CLIN ORTHOP RELAT R, P270
[4]  
BERESFORD JN, 1992, J CELL SCI, V102, P341
[5]  
BROCKBANK KGM, 1986, EXP HEMATOL, V14, P386
[6]  
Bruder SP, 1997, J CELL BIOCHEM, V64, P278, DOI 10.1002/(SICI)1097-4644(199702)64:2<278::AID-JCB11>3.0.CO
[7]  
2-F
[8]   MESENCHYMAL STEM-CELLS [J].
CAPLAN, AI .
JOURNAL OF ORTHOPAEDIC RESEARCH, 1991, 9 (05) :641-650
[9]   Effect of chemotherapy for acute myelogenous leukemia on hematopoietic and fibroblast marrow progenitors [J].
CarloStella, C ;
Tabilio, A ;
Regazzi, E ;
Garau, D ;
LaTagliata, R ;
Trasarti, S ;
Andrizzi, C ;
Vignetti, M ;
Meloni, G .
BONE MARROW TRANSPLANTATION, 1997, 20 (06) :465-471
[10]   Retroviral vector-modified bone marrow stromal cells secrete biologically active factor IX in vitro and transiently deliver therapeutic levels of human factor IX to the plasma of dogs after reinfusion [J].
Cherington, V ;
Chiang, GG ;
McGrath, CA ;
Gaffney, A ;
Galanopoulos, T ;
Merrill, W ;
Bizinkauskas, CB ;
Hansen, M ;
Sobolewski, J ;
Levine, PH ;
Greenberger, JS ;
Hurwitz, DR .
HUMAN GENE THERAPY, 1998, 9 (10) :1397-1407